Pomalidomide in multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2016.1274973
Abstract: The recent introduction of novel agents (thalidomide, lenalidomide, and bortezomib) has impacted favorably on the survival of multiple myeloma (MM) patients. However, prognosis is poor for those who relapse or are refractory (RR) to lenalidomide… read more here.
Keywords: multiple myeloma; pomalidomide multiple; lenalidomide bortezomib; myeloma ... See more keywords